Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 138,967,760
  • Shares Outstanding, K 594,184
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 60-Month Beta 1.12
  • Price/Sales 5.82
  • Price/Cash Flow 12.88
  • Price/Book 12.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 3.39
  • Number of Estimates 11
  • High Estimate 3.83
  • Low Estimate 3.08
  • Prior Year 3.42
  • Growth Rate Est. (year over year) -0.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
213.55 +8.77%
on 11/14/19
235.80 -1.50%
on 12/02/19
+17.19 (+7.99%)
since 11/05/19
3-Month
188.78 +23.04%
on 10/02/19
235.80 -1.50%
on 12/02/19
+24.62 (+11.86%)
since 09/05/19
52-Week
166.30 +39.67%
on 05/15/19
235.80 -1.50%
on 12/02/19
+34.51 (+17.45%)
since 12/04/18

Most Recent Stories

More News
Amgen Inc Shares Up 15.3% Since SmarTrend's Buy Recommendation (AMGN)

SmarTrend identified an Uptrend for Amgen Inc (NASDAQ:AMGN) on October 14th, 2019 at $203.07. In approximately 2 months, Amgen Inc has returned 15.30% as of today's recent price of $234.13.

AMGN : 232.00 (-0.80%)
Biogen's Shares Down on Rating Downgrade by Baird Analyst

Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.

NVS : 91.74 (+0.20%)
RHHBY : 38.4640 (-0.15%)
AMGN : 232.00 (-0.80%)
BIIB : 287.52 (-0.69%)
Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer

Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.

GSK : 44.86 (-0.47%)
PFE : 37.91 (-0.60%)
MRK : 88.25 (-0.47%)
AMGN : 232.00 (-0.80%)
Abarca, Amgen Enter Outcome-Based Agreement For Enbrel

Abarca, a pharmacy benefit manager (PBM) that is disrupting the industry with an entirely new approach to technology and business practices, today announced it has entered into an outcomes-based contract...

AMGN : 232.00 (-0.80%)
Amgen Announces Data Being Presented At ASH 2019

Amgen (NASDAQ:AMGN) today announced new clinical data from its oncology in-line products and pipeline that will be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition...

AMGN : 232.00 (-0.80%)
Global Chemotherapy-Induced Anemia Market Spotlight Report 2019: Pfizer's Epogen Biosimilar Retacrit Launches at 33% Off in a US Market where Amgen's Already Competitive - ResearchAndMarkets.com

The "Market Spotlight: Chemotherapy-Induced Anemia" report has been added to ResearchAndMarkets.com's offering.

AMGN : 232.00 (-0.80%)
4,000 Peterborough students receive lifesaving CPR and defibrillator training during CPR month

To mark CPR Month, today the Advanced Coronary Treatment (ACT) Foundation and partners, launched the ACT High School CPR and Defibrillator Training Program in 18 Peterborough and area high schools. This...

AMGN : 232.00 (-0.80%)
HRNNF : 18.8667 (+1.32%)
H.TO : 25.68 (+0.71%)
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

GBT : 74.97 (+1.06%)
ICPT : 118.37 (+0.62%)
AMGN : 232.00 (-0.80%)
CCXI : 27.82 (-0.93%)
CBAY : 1.65 (+0.61%)
Here's Why Merck's (MRK) Shares Are Up This Year

Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.

MRK : 88.25 (-0.47%)
AZN : 47.67 (-1.10%)
PFE : 37.91 (-0.60%)
AMGN : 232.00 (-0.80%)
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer

Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.

MRK : 88.25 (-0.47%)
PFE : 37.91 (-0.60%)
INCY : 94.15 (-0.89%)
AMGN : 232.00 (-0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 236.48
1st Resistance Point 235.18
Last Price 232.33
1st Support Level 232.29
2nd Support Level 230.70

See More

52-Week High 235.80
Last Price 232.33
Fibonacci 61.8% 209.25
Fibonacci 50% 201.05
Fibonacci 38.2% 192.85
52-Week Low 166.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar